The patent landscape in the field of stem cell therapy: closing the gap between research and clinic

• Published in: F1000 research Vol. 11; p. 997
• Main Authors: Hernández-Melchor, Dinorah, López-Bayghen, Esther, Padilla-Viveros, América
• Format: Journal Article
• Language: English
• Published: London Faculty of 1000 Ltd 01.01.2022
• Subjects: Cell therapy; Embryos; Federal court decisions; Intellectual property; Licenses; Market entry; Morality; Nonprofit organizations; Researchers; Stem cells; Therapeutic applications; United States > US; Europe
• ISSN: 2046-1402; 2046-1402
• DOI: 10.12688/f1000research.123799.4

Stem cell technology is a powerful tool ready to respond to the needs of modern medicine that is experiencing rapid technological development. Given its potential in therapeutic applications, intellectual property rights (IPR) as a protection resource of knowledge are a relevant topic. Patent eligibility of stem cells has been controversial as restrictions to access the fundamental technologies open a gap between research and clinic. Therefore, we depicted the current patent landscape in the field to discuss if this approach moves forward in closing this breach by examining patent activity over the last decade from a transdisciplinary perspective. Stem cell therapeutic applications is an area of continuous growth where patent filing through the PCT is the preferred strategy. Patenting activity is concentrated in the USA, European Union, and Australia; this accumulation in a few key players leads to governance, regulation, and inequality concerns. To boost wealthiness and welfare in society - stem cell therapies' ultimate goal - while at post-pandemic recovery, critical elements in the field of IPR rise to overcome current limitations: to promote bridge builders able to connect the research and business worlds, regulatory updates, novel financing models, new vehicles (startups, spinouts, and spin-offs), and alternative figures of intellectual property.